Furthermore, we discuss emerging therapeutic strategies for KMT2C-deficient breast cancers, such as epigenetic modulators (EZH2 inhibitors, KDM6A inhibitors, and BET inhibitors), DNA damage response (DDR)-targeting agents, and pathway-specific inhibitors. Here, KMT2C is linked to breast carcinoma.